EMA Authorised: Orserdu (elacestrant) — Stemline Therapeutics B.V.

View source ↗

Summary

EMA authorised Orserdu (elacestrant) for breast neoplasms, marking approval under Stemline Therapeutics B.V. as MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• Orserdu (Elacestrant)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Stemline Therapeutics B.V.. Decision date: 29/07/2026